Effectiveness of Combination Therapy of Sofosbuvir and Daclatasvir in Hepatitis C Positive Hemodialysis Patients Presenting to a Tertiary Care Hospital

Abstract

Objective: To determine the frequency of sustained virological response (SVR) after treatment with Sofosbuvir and
daclatasvir among hepatitis C positive hemodialysis patients presenting to a tertiary care hospital.

Study Design: Descriptive case series.

Place and Duration of Study: Department of Nephrology, Sharif Medical City, Lahore Pakistan, from Mar to Dec 2019.

Methodology: Total 62 hepatitis C positive hemodialysis patients undergoing regular hemodialysis in the Heamodialysis
unit of Sharif Medical City, Lahore and fulfilling the selection criteria were enrolled in the study after an informed consent.
Information regarding their demographic data was noted in the proforma. All the patients were advised 400 mg of
sofosbuvir on alternate day along with 60mg daclatasvir once daily for 12 weeks. At the end of 12 weeks of therapy, all
patients were undergone qualitative PCR and effectiveness of the treatment was noted on the basis of qualitative PCR. In
order to see SVR 12 PCR was repeated after 12 weeks and SVR labeled as operational definition.

Results: Total 62 patients were enrolled in the study. Their mean age was 36.52±14.03 years with range from 15-60 years.
The minimum duration of dialysis was 3 months and maximum was 10 months. Body mass index ranged from 25-32 kg/m2
with mean 28.37±2.29 kg/m2. There were 53.2% male patients and 46.8% were female patients. SVR-12 was achieved in
82.3% patients while 17.7% patients failed to respond No association was found between SVR-12 and age, sex, BMI or
duration....
Conclusion: Treatment with Sofosbuvir and daclatasvir among hepatitis C positive .......